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Abstract
Background: Initially described as an early onset seizure variant of Rett syndrome, the CDKL5 disorder is now
considered as an independent entity. However, little is currently known about the full spectrum of comorbidities
that affect these patients and available literature is limited to small case series. This study aimed to use a large
international sample to examine the prevalence in this disorder of comorbidities of epilepsy, gastrointestinal problems
including feeding difficulties, sleep and respiratory problems and scoliosis and their relationships with age and genotype.
Prevalence and onset were also compared with those occurring in Rett syndrome.
Methods: Data for the CDKL5 disorder and Rett syndrome were sourced from the International CDKL5 Disorder Database
(ICDD), InterRett and the Australian Rett syndrome Database (ARSD). Logistic regression (multivariate and univariate) was
used to analyse the relationships between age group, mutation type and the prevalence of various comorbidities.
Binary longitudinal data from the ARSD and the equivalent cross-sectional data from ICDD were examined using
generalized linear models with generalized estimating equations. The Kaplan-Meier method was used to estimate
the failure function for the two disorders and the log-rank test was used to compare the two functions.
Results: The likelihood of experiencing epilepsy, GI problems, respiratory problems, and scoliosis in the CDKL5
disorder increased with age and males were more vulnerable to respiratory and sleep problems than females. We
did not identify any statistically significant relationships between mutation group and prevalence of comorbidities.
Epilepsy, GI problems and sleep abnormalities were more common in the CDKL5 disorder than in Rett syndrome whilst
scoliosis and respiratory problems were less prevalent.
Conclusion: This study captured a much clearer picture of the CDKL5 disorder than previously possible using the
largest sample available to date. There were differences in the presentation of clinical features occurring in the
CDKL5 disorder and in Rett syndrome, reinforcing the concept that CDKL5 is an independent disorder with its own
distinctive characteristics.
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Background
The CDKL5 disorder is a rare X-linked neurodevelop-
mental disorder caused by a disruption in the cyclin
dependent kinase-like 5 (CDKL5) gene [1]. Mutations in
this gene were originally identified in children with West
syndrome, X-linked infantile spasms and principally in
those with the early seizure onset form of Rett syndrome
[1, 2]. Later research however demonstrated that less
than one quarter of CDKL5 cases would actually meet
the criteria for this atypical form of Rett syndrome [3].
Therefore, the CDKL5 disorder has been further defined
as an independent disorder, characterized by early-onset
intractable seizures, severely impaired gross motor skills
and global developmental delay with sleep disturbances,
abnormal muscle tone, bruxism and gastrointestinal issues
also occurring commonly [3]. Less common features are
hand stereotypies, laughing and screaming spells, breath-
ing disturbances, peripheral vasomotor disturbances and a
range of dysmorphic features. The latter include a broad/
prominent forehead, large “deep-set” eyes, full lips, tapered
fingers and anteverted nares [3].
Rett syndrome is a well-studied rare neurodevelopmental
disorder caused by a mutation in the methyl CpG binding
protein 2 (MECP2) gene [4]. Like the CDKL5 disorder, it is
associated with severe disability and multiple comorbidities
including scoliosis, breathing disturbances and sleep abnor-
malities [5–12]. A worldwide infrastructure which includes
the Australian and International Rett syndrome (InterRett)
databases [13, 14] and the US Natural History study [15]
has enabled the clinical picture and variation in Rett syn-
drome to be understood.
Unlike Rett syndrome, very little is known about the
full range of comorbidities occurring in the CDKL5 dis-
order with available literature mainly limited to small
case series or studies [1–3, 16–32]. The establishment of
an international database for the CDKL5 disorder [23], a
data repository designed to build a large sample size and
facilitate future genotype-phenotype relationships, has
provided opportunity to examine these poorly researched
clinical aspects. The current study has used this database
to examine the prevalence of comorbidities of epilepsy,
gastrointestinal problems including feeding difficulties,
sleep and respiratory problems and scoliosis in individuals
with the CDKL5 disorder, and their relationships with age
and genotype. The prevalence and onset of comorbidities
in the CDKL5 disorder were then compared with those
occurring in Rett syndrome.
Method
Data sources
Data for the CDKL5 disorder were sourced from the
International CDKL5 Disorder Database (ICDD) with sup-
plementation of a small number of cases from InterRett,
the International Rett Syndrome Database. The ICDD
(http://cdkl5.childhealthresearch.org.au) was established
in 2012 with the purpose of collecting information
internationally on individuals with the CDKL5 disorder.
A CDKL5 disorder specific questionnaire was formu-
lated to capture comprehensively the clinical features
and natural history of the disorder [23]. Individuals were
included in this study if their CDKL5 mutation was con-
sidered to be pathogenic or probably pathogenic and
when at least one relevant section of the questionnaire
had been completed. As the CDKL5 disorder was initially
considered to be an atypical form of Rett syndrome, data
on individuals with the CDKL5 disorder were initially in-
cluded in InterRett, an international phenotype database
that collects data worldwide on the clinical features and
genetic characteristics of individuals with Rett syndrome
[14]. For the majority of these cases, the data subsequently
provided to ICDD was used for this study, but for a small
proportion ICDD data was not available and thus we
used InterRett data to allow inclusion of these cases in
the study.
Data for Rett syndrome comorbidities was available from
follow-up data collected up to 2011 in the population-
based Australian Rett Syndrome Database (ARSD), a longi-
tudinal database that collects information from families
and clinicians [33]. Questionnaires are administered on
recruitment and since 2000, additional follow-up ques-
tionnaires have also been sent to families every 2 to 3
years [34].
Ethics approval for this study was provided by the
University of Western Australia Human Research Ethics
Committee (RA/4/1/5024).
Covariates
The covariates included age group, gender, mutation
type and for comparative purposes the type of disorder
(CDKL5 disorder and Rett syndrome). Age at registration
to ICDD was grouped into three categories (< 5 years, 5
to < 10 years, ≥ 10 years) consistent with the age distribu-
tion of the study sample, which comprised mainly of
young children and few adults (9/167, 5.4 %). Due to the
large number of different individual CDKL5 gene muta-
tions and the few recurrent mutations, the mutation types
were categorized as previously [23] according to their
predicted structural and functional consequences [35].
Mutations were grouped as: (A) no functional protein,
comprising any mutation that prevents function in the
catalytic domain; (B) missense/in-frame mutations within
catalytic domain, including any missense mutation within
the protein kinase active region or in-frame mutation that
results in loss of some kinase region (with consequent
protein intact) due to deletion; (C) truncation occurring
between aa172 and aa781, including any truncations such
as nonsense or frameshift mutations that cause loss of c-
terminal region whilst maintaining kinase activity; and (D)
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late truncation occurring after aa781 including truncations
that maintains the kinase activity and a large portion of
c-terminal region [35].
Outcomes
CDKL5 Age of onset and current seizure frequency
(daily, weekly, monthly or less frequent than monthly)
were used to characterise epilepsy. Parents were asked
to report whether their child had ever and currently had
constipation, reflux and air swallowing; the method of
feeding (oral, enteral or a combination); ability to self-
feed (independent, assisted or dependent) restricted to
children aged 2 years or more, the occurrence/frequency
of coughing during meals for those who fed orally; and
the age at gastrostomy insertion. They were also re-
quested to report on the presence of any sleep problems
and specific problems of night waking and night laughing,
and to complete the Sleep Disturbances Scale for Children
(SDSC). The SDSC is a 26 item self-report scale, which
allows parents to rate their children’s sleep behaviour
using a 5-point Likert scale during the previous 6 months
[36]. Information was sought on respiratory problems
included the presence and frequency of breathing irregu-
larities (hyperventilation, breath holding) such as those
found in Rett syndrome [11]. Furthermore, we asked
parents to report on episodes of respiratory illnesses in-
cluding pneumonia and aspiration over their child’s life
course, and also on their trajectory of hospitalisations by
cause. The impacts of lower respiratory tract infections
over 5-year intervals were also estimated by parents. Infor-
mation was also requested on the presence of scoliosis,
age of diagnosis and type of treatment (physical, bracing,
spinal surgery).
Rett syndrome Information was available on age of
onset of epilepsy, and gastrostomy insertion; and the
presence of sleep problems, gastrointestinal problems
and irregular breathing patterns at various time-
points in the life of the individual. The occurrence of
lower respiratory tract infections over the life course
prior to the initial follow-up questionnaire and during
previous 12-month periods for subsequent follow-up
questionnaires was also available. Recently published
information was used for estimates of age of onset of
scoliosis [37].
Statistical analyses
Descriptive statistics were used to characterise the co-
morbidities (epilepsy, gastrointestinal problems, feeding
difficulties, sleep abnormalities, respiratory problems
and scoliosis) in individuals with CDKL5 disorder and Rett
syndrome. Logistic regression (multivariate and univariate)
was used to analyse the associations between age group,
mutation type and the prevalence of various comorbidities.
Multinomial logistic regression was used to investigate the
relationship between the frequencies of coughing during
meals and the independent variables. Odds ratios and beta
coefficient values were examined to interpret the effect
sizes. Sleep scores (SDSC) of individuals with CDKL5 dis-
order were compared with a normal population sample
[36] using two-sample t-test with unequal variance. The
incidence rate of hospitalisation (in 100 person-years) was
determined using the number of hospitalisations over the
total person-time of the hospitalised individuals.
The comparison with Rett syndrome was restricted to
females for both disorders such that males with the
CDKL5 disorder were excluded. Binary longitudinal data
from the ARSD and the equivalent cross-sectional data
from ICDD were examined using generalized linear model
with generalized estimating equations. This accounted for
clustering within individuals, to estimate the effect of the
type of disorder on the likelihood of selected comorbidi-
ties after adjusting for age. Log link function, robust
standard errors and exchangeable working correlation
structures were used in the model for parameter estima-
tion. For time to event analysis, the Kaplan-Meier method
was used to estimate the failure function for the two disor-
ders and the log-rank test was used to compare the two
functions. Event time was defined as the age at onset of
scoliosis, epilepsy or gastrostomy or the age of ascertain-
ment if censored. STATA (Version 13, StataCorp, College
Station, TX, USA) was used for statistical analysis.
Results
As of June 2015, there were 167 confirmed cases with a
pathogenic CDKL5 mutation registered either with
ICDD (n = 151) or InterRett (n = 16). Age at registration
ranged from 3.9 months to 29.1 years (median age
5.9 years). The majority (85.6 %, n = 143) were females
(median age 5.9 years, range 3.9 months to 29.1 years)
and 14.4 % (n = 24) were males (median age 5.8 years,
range 10.5 months to 24.5 years). Sufficient mutation de-
tails were available for 164 cases to enable classification
into mutation groups based on the structure and func-
tion of the CDKL5 gene. Case distribution, according to
gender, age group, mutation group and comorbidities is
shown in Table 1, and the distribution of comorbidities
by mutation group is shown in Table 2.
Epilepsy in the CDKL5 disorder
Families of all (98.0 %, 145/148) but two females and
one male reported that their child had experienced one
or more episodes of seizures. The median age of epilepsy
onset was 6 weeks (range 1 day to 1.5 years). Information
on current seizure frequency was available for 137/145.
Ninety-five individuals (69.3 %, 95/137) were experiencing
seizures daily with their average frequency of daily seizures
ranging from one to 21 seizures. Of those who provided
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information on the number of daily seizures (n = 82), the
majority (56/82) were experiencing fewer than five sei-
zures a day, 18/82 between five and ten seizures, and 8/82
more than 10 seizures every day. Otherwise, almost
13.9 % (19/137) were having seizures approximately
weekly, 9.5 % (13/137) monthly and one individual
(0.7 %) only occasionally experienced seizures. Nine
individuals (6.6 %) had had no seizures for more than
a year.
Gastro-intestinal health in the CDKL5 disorder
The majority (86.5 %, 122/141) of the individuals were
reported to have experienced at least one gastrointestinal
(GI) problem including constipation (70.9 %), reflux
(64.1 %) and air swallowing (27.1 %) (Table 1). Children
aged 10 years or older had 3.5 times the odds of cur-
rently experiencing a GI problem compared to children
under 5 years (odds ratio (OR) 3.5, 95 % confidence
interval (CI) 1.22, 10.08) after adjusting for mutation
Table 1 Frequency distribution of age, mutation type and prevalence of comorbidities by gender
Female (n = 143) Male (n = 24) Total (n = 167)
n/N (%) n/N (%) n/N (%)
Age group
0 < 5 years 58/143 (40.6) 12/24 (50.0) 70/167 (41.9)
5 < 10 years 49/143 (34.3) 6/24 (25.0) 55/167 (32.9)
10 years or older 36/143 (25.2) 6/24 (25.0) 42/167 (25.2)
Mutation group
No functional protein 41/141 (29.1) 10/23 (43.5) 51/164 (31.1)
Missense/in-frame mutation within catalytic domain 39/141 (27.7) 6/23 (26.1) 45/164 (27.4)
Truncation between aa172 and aa781 37/141 (26.2) 1/23 (4.4) 38/164 (23.2)
Truncation after aa781 15/141 (10.6) 2/23 (8.7) 17/164 (10.4)
Mutation not grouped 9/141 (6.4) 4/23 (17.4) 13/164 (7.9)
Epilepsy ever 128/130 (98.5) 17/18 (94.4) 145/148 (98.0)
GI health
Any GI problem ever 106/123 (86.2) 16/18 (88.9) 122/141 (86.5)
Constipation ever 85/123 (69.1) 15/18 (83.3) 100/141 (70.9)
Reflux ever 72/111 (64.9) 10/17 (58.8) 82/128 (64.1)
Air swallowing ever 32/116 (27.6) 4/17 (23.5) 36/133 (27.1)
Gastrostomy ever 31/127 (24.4) 11/19 (57.9) 42/146 (28.8)
Sleepa
Any sleep problem ever 106/124 (85.5) 16/17 (94.1) 122/141 (86.5)
Night waking 63/106 (59.4) 9/17 (52.9) 72/123 (58.5)
Diurnal problemsb 51/108 (47.2) 8/18 (44.4) 59/126 (46.8)
Teeth grinding 41/108 (38.0) 9/18 (50.0) 50/126 (39.7)
Night screaming 25/109 (22.9) 4/18 (22.2) 29/127 (22.8)
Night laughing 28/109 (25.7) 6/18 (33.3) 34/127 (26.8)
Repetitive actions while falling asleep 29/107 (27.1) 4/18 (22.2) 33/125 (26.4)
Respiratory
Any breathing irregularities 33/110 (30.0) 8/16 (50.0) 41/126 (32.5)
Hyperventilation 15/109 (13.8) 2/16 (12.5) 17/125 (13.6)
Breath-holding 26/109 (23.9) 7/16 (43.8) 33/125 (26.4)
Pneumonia ever 18/109 (16.5) 9/17 (52.9) 27/126 (21.4)
Aspiration 19/107 (17.8) 9/17 (52.9) 28/124 (22.6)
Scoliosis 23/122 (18.9) 5/16 (31.3) 28/138 (20.3)
aIndividuals with frequent sleep problems (1–2 times per week, 3–5 times per week and daily) only
bDiurnal problems: daytime napping
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(Table 3). Compared to the no functional protein
group, individuals with a missense/in-frame mutation
within catalytic domain and truncation after aa172 had
higher odds of air swallowing (Table 3). The odds of ex-
periencing constipation, reflux or air swallowing also
increased with age, especially in those over 10 years
(Table 3). The odds of experiencing constipation (OR
0.90, 95 % CI 0.28, 2.90) or reflux (OR 1.01, 95 % CI
0.31, 3.34) were similar for both males and females.
Feeding difficulties and methods of feeding in the
CDKL5 disorder
Nearly four-fifths of the affected individuals (79.3 %,
107/135) were reported to eat and drink orally. Of
these, 12 children had had a feeding tube inserted for
other purposes such as venting gas and administration
of nutritional supplements or medications. Twenty-
eight individuals (20.7 %) were exclusively enterally
fed (gastrostomy tube or nasogastric tube feeding).
Use of nasogastric tube feeding was uncommon
(2.2 %, 3/135).
Feeding difficulties were reported for over a half
(50.9 %, 48/95) of the orally fed individuals with 60 %
(45/75) of the children over 2 years of age completely
dependent on their families for eating and drinking. A
much smaller number (5.3 %, 4/75) of children were
able to eat/drink independently; some (16.0 %, 12/75)
could finger feed with assistance or were assisted with
spoon-feeding (18.7 %, 14/75). Almost three-quarters
(73.4 %, 69/94) of the parents reported at least occa-
sional (>1/week) coughing during oral feeding. There
were some evidence to suggest that the relative risk of
coughing (sometimes or often vs never) during feeding
was greatest in those under 5 years (Table 4). Relation-
ships between coughing, gender and genotype are also
shown in Table 4.
Table 2 Prevalence of comorbidities by mutation group in 164 individuals with the CDKL5 disorder
No functional
protein (n = 51)
Missense/in-frame mutation within
catalytic domain (n = 45)
Truncation between aa172
and aa781 (n = 38)
Truncation after
aa781 (n = 17)
n/N (%) n/N (%) n/N (%) n/N (%)
Epilepsy ever 47/48 (97.6) 39/40 (96.8) 32/32 (100.0) 16/16 (100.0)
GI health
Any GI problem 30/43 (69.8) 28/38 (73.7) 18/30 (60.0) 9/14 (64.3)
Constipation 20/43 (46.5) 23/40 (57.5) 20/31 (64.5) 6/15 (40.0)
Reflux ever 16/40 (40.0) 17/34 (50.0) 11/29 (37.9) 3/13 (23.1)
Air swallowing 2/41 (4.9) 10/38 (26.3) 7/30 (23.3) 4/15 (26.7)
Gastrostomy ever 14/45 (31.1) 14/41 (34.2) 8/32 (25.0) 3/16 (18.8)
Sleepa
Any sleep problem ever 41/45 (91.1) 35/40 (87.5) 24/30 (80.0) 14/16 (87.5)
Persistent night waking 26/39 (66.7) 21/33 (63.6) 14/28 (50.0) 6/12 (50.0)
Diurnal problemsb 18/41 (43.9) 19/34 (55.9) 13/28 (46.4) 6/12 (50.0)
Teeth grinding 15/40 (37.5) 13/34 (38.2) 11/28 (39.3) 4/13 (30.8)
Night screaming 11/40 (27.5) 12/35 (34.3) 2/28 (7.1) 2/13 (15.4)
Night laughing 12/40 (30.0) 12/35 (34.3) 6/28 (21.4) 1/13 (7.7)
Repetitive actions while
falling asleep




12/41 (29.3) 14/35 (40.0) 8/30 (26.7) 1/9 (11.1)
Hyperventilation 3/44 (6.8) 3/34 (17.7) 5/30 (16.7) 1/9 (11.1)
Breath-holding 11/41 (26.8) 11/33 (33.3) 6/30 (20.0) 1/10 (10.0)
Pneumonia ever 10/42 (23.8) 5/33 (15.2) 6/28 (21.4) 3/12 (25.0)
Aspiration ever 12/41 (29.3) 6/33 (18.2) 6/27 (22.2) 1/12 (8.3)
Scoliosis 9/44 (20.5) 9/40 (22.5) 7/30 (23.3) 2/15 (13.3)
aindicates that only individuals with frequent sleep problems (1–2 times per week, 3–5 times per week and daily rather than monthly or less frequently) were
classified as having the sleep problem
bDiurnal problems: daytime napping
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Table 3 Multivariate logistic regression analysis of current gastrointestinal problems by age, gender and mutation group (n = 164)
Any GI problem Constipation Reflux Air swallowing
(n = 94) (n = 73) (n = 51) (n = 25)
n (%) OR (95 % CI) p value n (%) OR (95 % CI) p value n (%) OR (95 % CI) p value n (%) OR (95 % CI) p value
N = 125 N = 129 N = 116 N = 110
Age group
0 to <5 years 50 (40.0) baseline – 52 (40.3) baseline – 48 (41.4) baseline – 44 (40.0) baseline –
5 to < 10 years 42 (33.6) 2.03 (0.83,4.94) 0.12 42 (32.6) 2.12 (0.90,5.00) 0.08 36 (31.0) 1.07 (0.42,2.72) 0.88 37 (33.6) 1.35 (0.37,4.86) 0.65
10 years or older 33 (26.4) 3.5 (1.22,10.08) 0.02 35 (27.1) 2.78 (1.14,6.74) 0.02 32 (27.6) 2.24 (0.88,5.71) 0.09 29 (26.4) 7.48 (1.96,28.53) 0.003
Gender
Female 112 (89.6) baseline – 115 (89.2) baseline – 102 (87.9) baseline – 110 (100) baseline –
Male 13 (10.4) 0.92 (0.25,3.44) 0.90 14 (10.9) 0.90 (0.28,2.90) 0.85 14 (12.1) 1.01 (0.31,3.34) 0.99 0 – –
Mutation group
No functional protein 43 (34.4) baseline – 43 (33.3) baseline – 40 (34.5) baseline – 34 (30.9) baseline –
Missense/in-frame mutation
within catalytic domain
38 (30.4) 1.27 (0.46,3.50) 0.64 40 (31.0) 1.62 (0.65,4.03) 0.30 34 (29.3) 1.73 (0.66,4.51) 0.27 34 (30.9) 12.14 (2.08,70.68) 0.01
Truncation between
aa172 and aa781
30 (24.0) 0.67 (0.24,1.89) 0.45 31 (24.0) 2.17 (0.80,5.91) 0.13 29 (25.0) 1.01 (0.36,2.82) 0.98 29 (26.4) 8.03 (1.35,48.00) 0.02
Truncation after aa781 14 (11.2) 0.81 (0.21,3.07) 0.76 15 (11.6) 0.74 (0.21,2.58) 0.64 13 (11.2) 0.49 (0.11,2.13) 0.34 13 (11.8) 14.21 (1.83,110.22) 0.01















Gastrostomy/jejunostomy in the CDKL5 disorder
Over a quarter (28.8 %, 42/146) of individuals had had a
gastrostomy or jejunostomy tube inserted due to various
and sometimes multiple reasons including feeding diffi-
culties (80.0 %), poor weight gain (60.0 %), difficulty with
administration of medications (62.9 %) and poor general
health and wellbeing (51.4 %).
Time to event analysis showed that males were more
likely to undergo gastrostomy than females (log rank test
p = 0.013) with a quarter of males having gastrostomy in-
sertion by age 2.6 (95 % CI 1.60, 4.34) compared to
7.4 years (95 % CI 4.64,-) for females (Fig. 1). No
particular differences were observed among the muta-
tion groups (log rank test p = 0.50).
Sleep in the CDKL5 disorder
The majority (86.5 %, 122/141) of individuals were re-
ported to have experienced a sleep problem during their
lifetime with current night waking occurring in 58.5 %
(72/123) (Table 1). The odds of sleep problems overall
were higher in the 5 to 10 year age group compared with
those younger than 5 years (OR 13.09, 95 % CI 1.57,
109.02), while the odds of night waking was lower in
Fig. 1 Estimated time-to-event functions of gastrostomy insertion for males and females with the CDKL5 disorder
Table 4 Multinomial logistic analysis of frequency of coughing by age group, gender and mutation group
Do not occur Sometimes occur Often occur
(n = 25) (n = 47) (n = 21)
n (%) n (%) RRR (95 % CI) p value n (%) RRR (95 % CI) p value
Age group
0 to <5 years 7 (28.0) 24 (54.6) – – 13 (61.9) – –
5 to <10 years 10 (40.0) 13 (46.4) 0.26 (0.07,1.01) 0.05 5 (23.8) 0.13 (0.02,0.73) 0.02
10 years or older 8 (32.0) 11 (22.9) 0.25 (0.06,0.98) 0.05 3 (14.3) 0.16 (0.03,0.91) 0.04
Gender
Female 23 (92.0) 44 (91.7) – – 19 (90.5) –
Male 2 (8.0) 4 (8.3) 1.83 (0.17,20.20) 0.62 2 (9.5) 0.80 (0.04,16.47) 0.88
Mutation group
No functional protein 8 (32.0) 15 (31.9) – – – – –
Missense/in-frame mutation within catalytic domain 6 (24.0) 12 (25.5) 1.05 (0.26,4.32) 0.94 6 (28.6) 1.32 (0.25,7.13) 0.74
Truncation between aa172 and aa781 6 (24.0) 12 (25.5) 1.30 (0.31,5.48) 0.72 4 (19.1) 1.10 (0.18,6.67) 0.92
Truncation after aa781 2 (8.0) 5 (10.6) 1.23 (0.19,8.05) 0.83 3 (14.3) 2.36 (0.26,21.16) 0.44
RRR relative risk ratio; CI confidence interval
Frequency of coughing grouped as the following: - do not occur (never); sometimes (less than 1/week and 1–2 times per week); often occur (daily and more
than 1/day)
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those with a truncation after aa172 than the no func-
tional protein group (Table 5).
The mean overall sleep disturbance score in those with
the CDKL5 disorder was higher than that in published
control subjects (two-sample t-test with unequal vari-
ance p < 0.001) [38] (Fig. 2). The majority of subscale
scores including disorders of initiating and maintaining
sleep, sleep breathing disorders, disorders of arousal,
sleep-wake transition disorders and disorders of exces-
sive somnolence were also higher (p < 0.001) (Fig. 2).
Breathing abnormalities in the CDKL5 disorder
Almost one-third (32.5 %, 41/126) were reported to have
breathing irregularities at the time of registration. These
included hyperventilation (13.6 %, 17/125) and breath
holding (26.4 %, 33/125) (Table 1). A history of pneumonia
was reported for 21.4 % (27/126) and aspiration for 22.6 %
(28/124) (Table 1). The odds of having an autonomic-type
breathing irregularity was higher in older individuals than
children younger than 5 years of age but the level of evi-
dence was low (Table 6). Males were more vulnerable than
females to experiencing apparent autonomic dysfunction
such as breath holding (OR 4.71, 95 % CI 1.30, 16.99), as
well as infections such as pneumonia (OR 7.51, 95 % CI
2.16, 26.09).
Families were asked to estimate the adverse impacts
(occasional or constant) of other acute illnesses in 5-year
intervals over their child’s lifetime (Table 7). During the
first 5 years of life, half (50.0 %, 62/124) of the families
reported that their child experienced problems due to ear
infections and over a third (37.1 % (46/124)) reported lower
respiratory tract infections (LRTI) such as pneumonia,
bronchitis and bronchiolitis (Table 7). All acute illnesses in-
cluding lower respiratory tract infections and urinary
tract infection became less problematic after the age
of 15 years (Table 7). Seizures, respiratory infections,
and other acute illnesses accounted for a total of 531
hospitalisations.
Seizure-related hospitalisations accounted for nearly
two-thirds (63.5 %, 337/531) of these hospitalisations
over 706.5 person-years with an incidence of 47.4 ad-
missions per 100 person-years. For the children of the
69/91 families with seizure-related admissions who
provided sufficient detail on these, the mean number
of days in hospital due to seizure-related events was
27.4 (median 19 days, range 1 day to 4.9 months). Re-
spiratory problems including aspiration, pneumonia,
bronchitis and bronchiolitis accounted for 62 hospitali-
sations (11.7 %). The incidence of respiratory-related
hospitalisations was 8.2 admissions per 100 person-years.
Thirty-seven (29.1 %, 37/127) individuals had had at least
one hospitalisation related to respiratory problems over
their lifetime.
Scoliosis in the CDKL5 disorder
The risk of developing scoliosis increased with age with
a 68.5 % (95 % CI 0.53, 0.80) likelihood of developing
scoliosis by age 10 years (Fig. 3). Physical treatments for
scoliosis had been undertaken for 39.3 % (11/28) of the in-
dividuals and mainly included bracing treatment (8/11).
Spinal surgery had been performed in 3 out of the 28 indi-
viduals (10.7 %).
Comparison with Rett syndrome
Follow-up data at one or more collection points were
available in the ARSD for 321 females with a pathogenic
MECP2 mutation. The median and range of ages of the af-
fected individuals for each of the follow up questionnaires
in the Australian Rett syndrome study were 13.0 years
(2.0–24.6), 13.8 years (2.8–27.3), 15.0 years (2.3–29.1),
15.8 years (2.6–30.8), 17.9 years (3.0–34.2) and 17.8 years
(2.6–35.5) for the questionnaire years 2000, 2002, 2004,
2006, 2009 and 2011 respectively.
The median age of epilepsy onset was much earlier in
females with the CDKL5 disorder (6.0 weeks) than Rett
syndrome (4.9 years) (Fig. 4) and the risk of developing
seizures was much greater in CDKL5 affected females
(log rank test p <0.001) during the observation period.
Sleep problems were highly prevalent in both disorders
but while night waking was more prevalent in the CDKL5
disorder than Rett syndrome, night laughing was less
prevalent as were gastrointestinal problems (except for
reflux), and autonomic-type breathing problems (Table 8).
However, the incidence of gastrostomy insertion was
higher in the CDKL5 disorder affected females (3.2 in-
sertions per 100 person-years) than in Rett syndrome
(1.9 insertions per 100 person-years). Females with CDKL5
disorder were more likely to have undergone gastrostomy
at an earlier age (log rank test (log rank test p = <0.001)
(Fig. 5). Compared with Rett syndrome, the relative
risks of having breathing irregularities such as hyper-
ventilation (RR 0.26, 95 % CI 0.16, 0.41) and breath
holding (RR 0.40, 95 % CI 0.28, 0.57) were lower in
CDKL5 disorder affected females. For respiratory infec-
tions, females with the CDKL5 disorder had a slightly
greater risk of having experienced pneumonia when com-
pared to Rett syndrome (RR 1.24, 95 % CI 0.62, 2.51).
However, those with Rett syndrome were more likely to
develop scoliosis than those with the CDKL5 disorder (log
rank test p = 0.002). The median age of scoliosis onset for
females with the CDKL5 disorder (14 years, 95 % CI 12, -)
was much later than in Rett syndrome (11 years, 95 % CI
10, 11.6) [39] (Fig. 6).
Discussion
This large-sample study using a CDKL5 disorder specific
database is the first to examine the comorbidities of the
CDKL5 disorder in depth and to compare their occurrence
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Table 5 Multivariate logistic analyses of any and specific current sleep problems by age, gender and mutation group
Any sleep problem Night waking Night screaming Night laughing
(n = 122) (n = 72) (n = 29) (n = 34)
n (%) OR (95 % CI) p value n (%) OR (95 % CI) p value n (%) OR (95 % CI) p value n (%) OR (95 % CI) p value
N = 131 N = 112 N = 116 N = 125
Age group
0 to <5 years 53 (40.5) baseline – 48 (42.9) baseline – 47 (40.5) baseline – 53 (42.4) baseline –
5 to < 10 years 42 (32.1) 13.09 (1.57,109.02) 0.02 36(32.1) 9.16 (2.91,28.86) <0.001 38 (32.8) 1.01 (0.34,3.02) 0.98 40 (32.0) 0.96 (0.32,2.92) 0.95
10 years or older 36 (27.5) 1.48 (0.45,4.84) 0.52 28 (25.0) 1.80 (0.67,4.85) 0.24 31 (26.7) 1.22 (0.41,3.67) 0.72 32 (25.6) 3.38 (1.20,9.53) 0.02
Gender
Female 116 (88.6) baseline – 98 (87.5) baseline – 101 (87.1) baseline – 107 (85.6) baseline –
Male 15 (11.5) 2.37 (0.27,20.53) 0.43 14 (12.5) 0.98 (0.27,3.53) 0.98 15 (12.9) 0.63 (0.16,2.53) 0.52 18 (14.4) 1.86 (0.38,4.05) 0.33
Mutation group
No functional protein 45 (34.4) baseline – 39 (34.8) baseline – 40 (34.5) baseline – 40 (34.5) baseline –
Missense/in-frame mutation within
catalytic domain
40 (30.5) 0.59 (0.14,2.49) 0.48 33 (29.5) 0.74 (0.26,2.12) 0.58 35 (30.2) 1.37 (0.50,3.78) 0.54 35 (30.2) 1.67 (0.58,4.78) 0.34
Truncation between aa172
and aa781
30 (22.9) 0.32 (0.08,1.33) 0.12 28 (25.0) 0.32 (0.10,0.99) 0.05 28 (24.1) 0.19 (0.04,0.98) 0.05 28 (24.1) 0.87 (0.26,2.89) 0.82
Truncation after aa781 16 (12.2) 0.41 (0.06,2.78) 0.37 12 (10.7) 0.24 (0.05,1.08) 0.06 13 (11.2) 0.48 (0.09,2.63) 0.40 13 (11.2) 0.22 (0.02,1.98) 0.18















with that of Rett syndrome. Epilepsy, GI problems and
sleep abnormalities were common in the CDKL5 disorder
whilst scoliosis and respiratory irregularities were less
prevalent than in Rett syndrome. The likelihood of experi-
encing epilepsy, GI problems, respiratory problems, and
scoliosis increased with age and males were more vulner-
able to respiratory and sleep problems than females. There
was no clear relationship between mutation group and
prevalence of comorbidities. However, mutations associ-
ated with late truncations after aa781 seemed to play some
protective role against GI problems, autonomic breathing
irregularities and sleep problems. It was also observed that
there were differences in clinical features occurring in
CDKL5 disorder and Rett syndrome, reinforcing the notion
that CDKL5 is an independent disorder with its own dis-
tinctive characteristics.
Consistent with previous studies, the early onset of
epilepsy (median age of onset 6 weeks) was a key feature
of CDKL5 disorder [18, 20]. Over three quarters were
experiencing at least one seizure daily. This highlights
the medical challenges in caring for children with the
CDKL5 disorder. As we had found previously in a
smaller study [3], GI disorders including constipation
and reflux were very common. For the first time we have
provided information about feeding difficulties and the
current method of feeding (oral or enteral feeding) in
the CDKL5 disorder. In this study, only two thirds were
still being fed orally and of these three-fifths were com-
pletely dependent on their families for eating and drinking.
This likely relates to the marked motor impairments asso-
ciated with this disorder [3]. Further, over half of those
who were orally fed experienced feeding difficulties in-
cluding dysphagia (abnormal swallowing) and related
symptoms such as coughing. As demonstrated in the
current study, one third had undergone a gastrostomy,
many at a young age where the purpose could have
been associated with assisting with feeding and/or epilepsy
management [38]. Gastrostomy insertions have been asso-
ciated with improved quality of life of both the caregivers
and child by reducing the stress associated with feeding
and also minimizing the dysphagia symptoms such as
coughing during feeding [39, 40].
Our large sample size has allowed us to characterize
sleep difficulties in the CDKL5 disorder in much greater
depth than was possible in previous small case series
[24, 27]. Night waking was the most persistently occur-
ring sleep problem, experienced by more than half of the
individuals in our study. In a French clinical study, 11/20
of affected females experienced sleep problems such as
night waking with screaming spells [19]. Similar findings
were demonstrated by Hagebeuk [24] and Pini et al. [27]
in two other case studies (n = 4 and n = 10) where all
subjects were observed to have experienced some sleep
abnormalities including disorders of initiation and main-
taining of sleep, sleep breathing disorders and daytime
somnolence. In our study, the Sleep Disturbance Scale for
Children was used to assess the various aspects of sleep
disturbances in a large sample with CDKL5 disorder for
the first time. When compared to normal healthy children
[36], the frequency of overall sleep disturbances (except
for night sweating) was higher in individuals with the
CDKL5 disorder. In particular, problems related to main-
taining and initiating sleep such as night waking and
sleep–wake disorders difficulties including startling while
falling asleep were frequently reported in this study. Simi-
lar to other neurodevelopmental disorders such as Autism
Spectrum Disorder and Angelman syndrome, genetic ab-
normalities that alter the neuronal pathways might be a
Fig. 2 Mean subscale scores of the SDSC in CDKL5 positive individuals (n = 124) and published controls (n = 1157). Figure legend: DIMS, disorders
of initiating and maintaining sleep; SBD, sleep breathing disorders; DA, disorders of arousal; SWTD, sleep-wake transition disorders; DOES, disorders
of excessive somnolence; SHY, sleep hyperhidrosis. Subscale scores ranges from 1 to 5 with highest score possible is 5 with higher scores indicating
more problematic sleep. The group data describing the healthy controls were derived from Bruni et al. [36]
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Table 6 Multivariate logistic regression analysis of respiratory problems by gender and mutation type
Any autonomic dysfunction Breath-holding Hyperventilation Respiratory problemab Pneumonia everb
(n = 41) (n = 33) (n = 17) (n = 28) (n = 27)
n (%) OR
(95 % CI)
p value n (%) OR
(95 % CI)
p value n (%) OR
(95 % CI)
p value n (%) OR
(95 % CI)
p value n (%) OR
(95 % CI)
p value
N = 115 N = 114 N = 117 N = 111 N = 115
Age group






baseline – 44(39.6) – – 47
(40.9)
– –












0.35 37(33.3) – – 37
(32.2)
– –







































































































0.30 10 (8.8) 0.29
(0.03,2.72)
0.28 9 (7.7) 1.52
(0.13,17.50)







OR odds ratio - the relative odds of having the outcome in the category of interest compared to the odds of having the outcome in the baseline category; CI confidence interval
aRespiratory problems that required hospital admission or doctor consultation















contributing factor to these sleep problems [41–44]. Even
though these mechanisms are unclear, other factors that
might be associated with these sleep disturbances include
abnormalities in the circadian rhythm, altered produc-
tion of neurotransmitters such as serotonin, periodic
limb movements, and presence of other comorbidities
such as uncontrollable seizures, scoliosis and gastro-
oesophageal reflux disease [42, 45, 46]. Sleep problems
have significant negative impact on the quality of life of
child and parents. Levels of parental stress have been
reported to be high among families of children with
neurodevelopmental disorders [47]. Perhaps in relation
to poor child sleep, parents of these children are likely
also to have poorer sleep, which could contribute to the
increased likelihood of depression and anxiety compared
with parents who do not have a child with a neurodeve-
lopmental disorder [45, 48].
Autonomic breathing irregularities including breath
holding and hyperventilation occurred in approximately
one third of our CDKL5 affected sample (32 %) compared
with 15/20 females in the French clinical study [19]. In an
Italian/Swedish case series of ten patients, respiratory dys-
rhythmia including forceful (n = 8) and apneustic breathing
(n = 2) types was present in all the ten females [27]. In the
same year, a Dutch study found out that two of the four
CDKL5 affected children observed had central apnoeas
when awake, preceded by recurrent episodic hyperventila-
tion [24]. The differences between the findings of our study
and these small case studies are not surprising; our larger
study sample allows a better estimation of the prevalence
of parent-reported breathing abnormalities. On the other
hand ours was an international epidemiological study with-
out the ability to measure autonomic and cardiorespiratory
function as was used to identify the cardiorespiratory
phenotype in those European patients [19, 24]. Therefore it
is also feasible that autonomic abnormalities occur in the
CDKL5 disorder without overt manifestations of breath
holding and hyperventilation.
Lower respiratory tract infections including pneumo-
nia were reported for over one fifth of the CDKL5
Table 7 Frequency distribution of various acute illnesses being sometimes or constantly problematic during 5-year epochs
<5 years 5 - < 10 years 10- <15 years 15 - < 20 years Over 20 years
n/N (%) n/N (%) n/N (%) n/N (%) n/N (%)
Lower Respiratory Tract Infectiona 46/124 (37.1) 12/58 (20.7) 18/23 (21.7) 1/9 (11.1) 1/8 (12.5)
Asthma 10/113 (8.1) 8/58 (13.8) 3/22 (13.6) 0/9 (0) 0/7 (0)
Urinary Tract Infection 21/123 (17.1) 13/56 (23.2) 6/23 (26.1) 1/9 (11.1) 0/7 (0)
Ear infection 62/124 (50.0) 14/56 (25.0) 2/22 (9.1) 1/8 (12.5) 0/7 (0)
Tonsillitis 10/123 (8.1) 7/58 (12.1) 2/23 (8.7) 0/9 (0) 0/7 (0)
The denominators of some variables are lower for older age groups due to children being younger at ascertainment and due to some missing data (some parents
have not responded)
aLower respiratory infection is comprised of infections including pneumonia, bronchitis and bronchiolitis
Fig. 3 Estimated time-to-event functions of developing scoliosis for males and females with the CDKL5 disorder
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affected individuals. This is an important issue especially
among the younger children that might relate to feeding
and swallowing difficulties, aspiration or difficulties in
expectorating chest secretions due to a poorly effective
cough. Aspiration of food or fluids into the lungs was
reported for nearly a quarter of the affected individuals.
Over a quarter were also unable to cough up chest se-
cretions, which might be a contributing risk factor for
aspiration because coughing is a protective mechanism
to prevent aspiration [49].
Approximately one third of individuals would have
developed scoliosis by the age of 10 years. In comparison
to other comorbidities, scoliosis was the least frequently
observed. The occurrence of scoliosis has been rarely re-
ported previously in the literature, possibly due to the
younger age distributions in these studies. A study by
Artuso et al. [17] reported absence of scoliosis in the
nine CDKL5 positive females (age range 1.2 to 13 years)
studied. The larger sample size of our study and compara-
tively wider age range of the participants allowed a better
estimation of the occurrence of scoliosis in CDKL5 disorder
because this is a comorbidity that develops over time.
Age can be considered as a risk factor for comorbidi-
ties such as epilepsy, GI and sleep problems, respiratory
issues and scoliosis. The likelihood of each of these co-
morbidities increased with age except for the frequency
Table 8 Comparison of various comorbidities in females with CDKL5 disorder (n = 143) and Rett syndrome (n = 321)
Comorbidity type Rett syndromea CDKL5 disorder RR (95 % CI) p value
n (%) n (%)
GI health
Any GI Problem 936/1181 (79.3) 82/120 (68.3) 0.85 (0.75–0.98) 0.02
Constipation 871/1181 (73.8) 65/123 (52.9) 0.72 (0.60–0.87) <0.001
Reflux 214/793 (27.0) 44/110 (40.0) 1.41 (1.03–1.92) 0.03
Respiratory
Hyperventilation 639/1175 (54.4) 15/109 (13.8) 0.26 (0.16–0.41) <0.001
Breath-holding 724/1176 (61.6) 26/109 (23.9) 0.40 (0.28–0.57) <0.001
Sleep
Night wakingb 422/591 (71.4) 96/110 (87.3) 1.18 (1.1–1.31) 0.03
Night screaming 483/1139 (42.4) 60/118 (50.9) 1.1 (0.86–1.32) 0.57
Night laughing 774/1139 (68.0) 70/122 (57.4) 0.76 (0.64–0.90) 0.001
Each individual in the AussieRett database could have contributed from one to six observations according to their participation in the initial and follow-up questionnaires,
which accounts for the large number of total observation (Rett syndrome)
RR risk ratio; CI confidence interval
aAverage prevalence for the 6 time points
bData for females with night waking (Rett syndrome) was only available from 2009 and 2011 questionnaires
Fig. 4 Estimated time-to-event functions of developing seizures for females with CDKL5 and Rett syndrome
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of coughing during feeding. Younger children would be
more prone to coughing as their small and narrow air-
ways get obstructed easily [50]. Over time, some would
have had gastrostomy insertions, which could explain
the reduced symptoms of dysphagia in older children.
The influence of gender on the prevalence of various
comorbidities was clearly evident. As generally reflected
in our data, males were more vulnerable to various re-
spiratory and sleep problems. X-inactivation (XCI) and
different degrees of skewing in females may result in
variable expression of CdKL5 protein, which may im-
prove the expression of the phenotype in females. XCI is
the transcriptional inactivation of one of the two X chro-
mosomes in females to functionally equalize the gene
dosage imbalance of X linked genes between XX females
and XY males [51]. Our recent study on developmental
milestones in this disorder, also using data from the
ICDD, reported that males were more affected overall
with more impaired development than females; this was
consistent with our results [23].
Even though no significant relationship between muta-
tion type and various comorbidities was found, there
were consistencies in the distribution of comorbidity
status by mutation group. For instance, there was some
evidence that mutations associated with late truncations
after aa781 may play a protective role against some GI
problems, autonomic breathing irregularities and sleep
problems compared to those with no function protein.
Fig. 5 Estimated time-to-event functions of gastrostomy insertion for females with CDKL5 disorder and Rett syndrome
Fig. 6 Estimated time-to-event functions of developing scoliosis for CDKL5 and Rett syndrome females
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Individuals with missense/in-frame mutations within the
catalytic domain appeared to have higher odds of having
any GI problems (constipation, reflux and air swallowing)
and autonomic breathing irregularities (hyperventilation
and breath-holding) when compared to those with no
functional protein. We previously showed that late
truncation mutations after aa781 were generally associ-
ated with a milder phenotype and had attained better
gross motor, hand function and communication skills
than those with other mutations [23]. Some genotype-
phenotype relationships were also found in the French
clinical series of 12 cases [20]. There patients with mis-
sense mutations in the catalytic domain (n = 4) had better
walking and hand use ability and less frequent refractory
epilepsy compared with those with mutations in the kinase
domain and frameshift mutations in the C-terminal region
(n = 7) who had a severe phenotype including infantile
spasms, frequent refractory epilepsy, severe motor impair-
ment and inability to walk.
There have been several studies [2, 32, 52] reporting on
overlapping similarities between the clinical features and
comorbidities of CDKL5 disorder and Rett syndrome. This
is thought possibly to be due to the same signalling path-
way shared by the CdKL5 and MeCP2 protein. Pini et al.
[27] suggests that there might be a direct phosphorylation
of MeCP2 protein by CdKL5 that has a kinase domain.
Despite the apparent similarities in many of the clinical
manifestations of the CDKL5 disorder and Rett syndrome,
there are some differences in their occurrence and onset
between the two disorders. Epilepsy is the hallmark feature
of CDKL5 disorder with almost every case having at least
some seizures. Epilepsy in CDKL5 disorder is character-
ized by complex partial seizures, infantile spasms, myo-
clonic and tonic seizures [17–19]. The onset of epilepsy is
much earlier (1.4 months) in the CDKL5 disorder than in
Rett syndrome (4.9 years). As reflected in our time-to-
event curve (Fig. 4), the risk of developing seizures was
significantly higher in CDKL5 affected females than those
with RTT during the first 20 years of age. In a study con-
ducted on 685 females with Rett syndrome using the
InterRett database, only one quarter of the females with
Rett syndrome had seizures by the age of 3 years [53].
Gastrointestinal problems except for reflux were slightly
less prevalent in CDKL5 affected females than Rett syn-
drome. Rett syndrome is generally associated with a high
prevalence of gastrointestinal dysmotility, feeding difficul-
ties and poor growth [6, 54, 55]. In a study by Motil et al.
[54], gastrointestinal problems (91 %) and feeding prob-
lems (81 %) were highly prevalent with gastroesophageal
reflux less prevalent. On the other hand, the incidence
of gastrostomy insertion was found to be slightly higher
in the CDKL5 disorder than Rett syndrome. A possible
explanation could be due to the use of gastrostomy for
purposes other than feeding difficulties in the CDKL5
disorder, especially for the administration of medica-
tions or the ketogenic diet needed to manage early on-
set and persistent seizures.
Sleep problems including night waking, screaming and
laughing were more likely to occur in the CDKL5 dis-
order than Rett syndrome. The likelihood of experien-
cing a sleep problem in the CDKL5 disorder increased
with age. The reason for this is not clear but it could relate
to the persistent and refractory epilepsy. Our findings also
suggest that autonomic dysfunction is less affected in
CDKL5 disorder than in Rett syndrome. On the other
hand, lower respiratory tract infections such as pneumo-
nia, were a little more likely to occur in CDKL5 affected
females than in those with Rett syndrome. This might be
due to increased occurrence of reflux and feeding difficul-
ties in CDKL5 disorder contributing to increased risk of
aspiration.
Our study comprised the largest number of individuals
with a confirmed pathogenic CDKL5 mutation to date
therefore enabling greater precision in our statistical es-
timates. This is the first time a CDKL5 specific question-
naire has been used to investigate the comorbidities of
the disorder. Engagement of the consumer reference
group in the development of the questionnaire also gives
strength to this study. The ICDD is growing and in time
will provide an even larger data repository for the better
understanding of various aspects of the CDKL5 disorder.
In addition, compared to the previous case series and
case studies, the age range of the individuals in the
CDKL5 registry is wide providing a better estimate of
the prevalence and characteristics of comorbidities, par-
ticularly those that develop with time.
There were some limitations in this study that might
impact the results. As the CDKL5 disorder questionnaire
asks parents to provide information of their child’s condi-
tion since birth, there is a possibility for some recall error.
To counter this, parents were asked to refer to their child’s
medical records and diaries before the completion of
questionnaire. Families did provide very extensive medical
histories about their children but we acknowledge this
was from a patient rather than a clinical perspective. An-
other limitation is that, a complete record of information
was not available from every confirmed case, as parents
may have completed different sections, resulting in vary-
ing denominators for various outcomes. Since the CDKL5
disorder is a condition that requires expensive genetic
testing for diagnosis, selection bias according to socioeco-
nomic status may be occurring. Families from higher so-
cioeconomic backgrounds are more likely to have the
financial capacity or insurance to cover the costs of
genetic testing, especially in countries such as USA where
the socioeconomic gradient is marked. This may result in
many individuals with a CDKL5 mutation remaining un-
diagnosed and thus excluded from the registry. This is a
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cross sectional data collection, and longitudinal data col-
lection similar to Rett syndrome [14] would be helpful to
understand the progression and severity of the clinical
features over time.
Conclusion
This study provides a comprehensive picture of comor-
bidities in the CDKL5 disorder. Being the largest sample
to date, the assumptions and results obtained gives a much
more precise insight into the phenotypic expression of this
disorder than was previously possible. Epilepsy, gastro-
intestinal and sleep problems were shown to be extremely
prevalent, whilst scoliosis and respiratory problems were
relatively less so. We have demonstrated that the impacts
of daily feeding and sleeping difficulties in CDKL5 disorder
both for the child and their family are issues of concern in
urgent need of further clinical research. There is also a
need to evaluate quality of life both for the child and their
family and for this to be considered as an important out-
come when investigating optimal strategies for managing
the many complexities of this disorder. Finally it is hearten-
ing to know that the growing size of the CDKL5 registry
will provide a valuable platform for further future study of
genotypic-phenotypic relationships in this disorder.
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